BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in San Antonio, Texas from October 16-20, 2023..

加利福尼亚州布里斯班-（商业线）-CareDx，Inc。（纳斯达克：CDNA）-移植公司™ 专注于为移植患者和护理人员发现，开发和商业化临床差异化的高价值医疗保健解决方案-今天宣布在美国组织相容性和免疫遗传学会（ASHI）第49届年会上牵头出席2023年10月16日至20日在德克萨斯州圣安东尼奥市举行。。

The latest advances across CareDx’s portfolio of HLA typing solutions and AlloSeq HCT for use in hematopoietic stem cell monitoring1 are being showcased across nineteen abstracts and two company-sponsored symposia. These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions..

CareDx的HLA分型解决方案和AlloSeq HCT用于造血干细胞监测1的最新进展正在19个摘要和两个公司赞助的专题讨论会上展示。这些同行评审的摘要展示了CareDx产品和解决方案的科学验证和实用性。。

“CareDx is proud to be a leading sponsor of this year’s ASHI meeting and driving continued innovation in transplantation with our best-in-class portfolio of HLA typing and workflow solutions,” said Reg Seeto, CEO and President of CareDx. “We are also excited to share the latest update on AlloSeq HCT, a transformative solution for chimerism monitoring in patients undergoing hematopoietic stem cell transplantation.”1.

CareDx首席执行官兼总裁Reg Seeto说：“CareDx很自豪成为今年ASHI会议的主要赞助商，并通过我们一流的HLA分型和工作流程解决方案组合推动移植方面的持续创新。“我们也很高兴分享AlloSeq-HCT的最新更新，AlloSeq-HCT是造血干细胞移植患者嵌合监测的变革性解决方案。”1。

For HLA laboratories, CareDx offers NGS-based typing solutions with AlloSeq Tx,1 QTYPE,1 SSP, and mTilda LIMS (Laboratory Information Management System). AlloSeq Tx171 delivers a novel method for matching transplant recipients and potential donors. The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.

对于HLA实验室，CareDx提供基于NGS的打字解决方案，包括AlloSeq Tx，1 QTYPE，1 SSP和mTilda LIMS（实验室信息管理系统）。AlloSeq Tx171提供了一种匹配移植受者和潜在捐赠者的新方法。匹配的混合捕获方法是CareDx独有的，与其他方法相比，它使实验室在基因内容上具有灵活性，并增强了鲁棒性。

mTilda LIMS software, virtual crossmatch, and epitope analysis are designed to improve transplant outcomes. For allogeneic hematopoietic stem cell transplant (allo-HCT) monitoring, AlloSeq HCT1 offers a streamlined and sensitive approach for NGS-based engraftment monitoring and surveillance following allo-HCT..

mTilda LIMS软件，虚拟交叉配型和表位分析旨在改善移植结果。对于异基因造血干细胞移植（allo-HCT）监测，AlloSeq HCT1为allo-HCT后基于NGS的植入监测和监测提供了简化而灵敏的方法。。

CareDx will host two symposia focused on “Innovation Across the Pre- and Post-Transplant Journey”:

CareDx将举办两次专题讨论会，重点讨论“移植前后的创新”：

Tuesday, October 17, moderated by Hal Gibson, Senior Vice President, Strategic Partnering, CareDx:

10月17日星期二，由CareDx战略合作高级副总裁Hal Gibson主持：

The History of Donor-Derived cfDNA in Transplantation. Robert Woodward, PhD, Chief Scientific Officer, CareDx.

供体来源的cfDNA在移植中的历史。Robert Woodward博士，CareDx首席科学官。

Evolving Clinical Utility of Donor-Derived Cell-DNA for Post-Transplant Management. Gaurav Gupta, MD, Professor of Medicine and Surgery, Interim Chief, VCU Division of Nephrology, Medical Director of Kidney/Pancreas Transplantation, Hume-Lee Transplant Center.

供体来源的细胞DNA在移植后管理中的临床应用进展。Gaurav Gupta，医学博士，医学和外科教授，VCU肾脏病学部临时主任，Hume Lee移植中心肾/胰腺移植医学主任。

Elevating the Standard of Care in Transplant Surveillance: Integrating Non-Invasive Biomarkers with Clinical Parameters. Carmen Lefaucheur, MD, Head of the Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital-APHP, Paris, France, and Professor of Nephrology at Université Paris Cité, Medical Director of the Paris Institute for Transplantation & Organ Regeneration, Director of the Research FHU Apollo..

提高移植监测的护理标准：将非侵入性生物标志物与临床参数相结合。Carmen Lefaucheur，医学博士，法国巴黎圣路易斯医院APHP肾脏病学和肾移植系主任，巴黎城市大学肾脏病学教授，巴黎移植与器官再生研究所医学主任，研究主任FHU阿波罗。。

Wednesday, October 18, moderated by Curtis Lind, Vice President, Head of R&D, Products, CareDx, and Michael Reardon, Senior Director, HLA Software Portfolio, CareDx:

10月18日星期三，由CareDx研发产品副总裁Curtis Lind和CareDx HLA软件组合高级总监Michael Reardon主持：

Latest Advances in AlloSeq Products & Software. Beata Kmiec, PhD, Product Manager, CareDx.

AlloSeq产品和软件的最新进展。Beata Kmiec博士，CareDx产品经理。

Revolutionizing Chimerism Analysis: Harnessing the Power of NGS and SNP Panels for Superior Results. Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.

革命性的嵌合分析：利用NGS和SNP面板的功能获得卓越的结果。Ahmed Mostafa，医学博士，博士，技术主管兼临床顾问，组织相容性和免疫遗传学实验室，圣保罗医院萨斯卡通。

Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR. Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI), Assistant Professor Department of Pathology, University of Utah.

虚拟交叉匹配和表位分析作为移植决策过程中的信息辅助：VXMatch和VECTR的回顾。Eszter Lazar Molnar博士，D（ABMLI），F（ACHI），犹他大学病理学助理教授。

About CareDx – The Transplant Company

关于CareDx-移植公司

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.

CareDx公司总部设在加利福尼亚州布里斯班，是一家领先的精准医学解决方案公司，致力于为移植患者和护理人员发现，开发和商业化临床差异化的高价值医疗解决方案。CareDx在移植前和移植后的患者旅程中提供测试服务，产品和数字医疗保健解决方案，并且是移植患者基于基因组学信息的领先供应商。

For more information, please visit: www.CareDx.com..

欲了解更多信息，请访问：www.CareDx.com。。

Forward Looking Statements

前瞻性声明

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s leading presence and sponsorship in 2023 ASHI meeting (the “Meeting”), AlloSeq HCT and its HLA typing solutions, and its presentation of the latest data on AlloSeq HCT and HLA typing solutions at the Meeting (the “Presentation”).

本新闻稿包括与CareDx，Inc.相关的前瞻性声明，包括关于CareDx在2023年ASHI会议（“会议”），AlloSeq HCT及其HLA领先的出席和赞助可能实现的潜在收益和结果的声明打字解决方案，以及在会议上介绍有关AlloSeq HCT和HLA分型解决方案的最新数据（“演示文稿”）。

These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its leading presence and sponsorship in the Meeting, AlloSeq HCT or its HLA typing solutions, or its Presentation; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and other reports that CareDx has filed with the SEC.

这些前瞻性声明基于CareDx当前可用的信息及其当前预期，仅在本协议签署之日起生效，并且存在可能导致实际结果与预期结果大不相同的风险和不确定性，包括CareDx未能实现其在会议中的领先参与和赞助，AlloSeq HCT或其HLA分型解决方案或其演示文稿的预期收益的风险；一般经济和市场因素；以及CareDx与SEC提交的文件中讨论的其他风险，包括CareDx于2023年2月27日向SEC提交的2022年12月31日止财政年度表格10-K年度报告，CareDx于2023年5月10日向SEC提交的2023年3月31日止季度表格10-Q季度报告，2023年8月8日由CareDx与SEC提交，以及CareDx已向SEC提交的其他报告。

Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements..

其中任何一项都可能导致CareDx的实际结果，绩效或成就与CareDx的前瞻性陈述所预期或暗示的实质性和不利影响有所不同。CareDx明确拒绝任何义务，除非法律要求，或承诺更新或修改任何此类前瞻性声明。。

References

工具书类

1. AlloSeq Tx17, AlloSeq HCT, and QTYPE are for research use only in the United States.

1.AlloSeq Tx17，AlloSeq HCT和QTYPE仅在美国供研究使用。